Endocyte, Inc. (NASDAQ:ECYT) declared that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide.

Por recordar El acuerdo alcanzado en 2012 entre Endocyte y Merck por el Prometedor Farmaco de la primera que estaba en la recta final de la Fase III para el Tratamiento de Cáncer de Ovario :

Merck pagará hasta US$1.000m a Endocyte por fármaco experimental .

16/04/12
DOW JONES NEWSWIRES

Merck & Co. (MRK) acordó pagar US$120 millones por adelantado a Endocyte Inc. (ECYT), con pagos adicionales de hasta US$800 millones, para desarrollar y comercializar el medicamento experimental para el cáncer Vintafolide, al tiempo que el laboratorio busca lanzar más medicamentos al mercado. Vintafolide está siendo evaluado en una fase 3 de pruebas clínicas para el cáncer de ovario y en una fase 2 de pruebas para el cáncer de pulmón no microcítico.

Zeltia Según EDISON . ( Informe Completo de 16 Paginas ) .

Zeltia is a holding company that is increasingly focused on the potentially high-growth marine oncology activities of PharmaMar. This subsidiary has a unique business model and has built a pipeline of first-in-class cancer drugs for development with strategic partners. Yondelis, its first product, sold in Europe since 2007, is approaching regulatory catalysts in the US and Japan. Other catalysts include Phase III Aplidin data (expected in 2015) and deal potential for PM01183 (shortly to begin pivotal trials). Approval(s), data and/or deal news should increase our €904m valuation.

...